Alnylam Pharmaceuticals
ALNY
164 hedge funds and large institutions have $3.27B invested in Alnylam Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 55 increasing their positions, 52 reducing their positions, and 22 closing their positions.
118% more capital invested
Capital invested by funds: $1.5B → $3.27B (+$1.77B)
118% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 22
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
21% more call options, than puts
Call options by funds: $27M | Put options by funds: $22.2M
18% more funds holding
Funds holding: 139 → 164 (+25)
6% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$103M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$96.1M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$87.7M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
+$31M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$21.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$45.6M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$31M |
| 3 |
BM
Bridger Management
New York
|
-$29.1M |
| 4 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
-$27.7M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$24.3M |
ALNY Hedge Fund Activity: Q3 2013 in Review
164 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2013, worth a combined $3.27B — up 118% from $1.5B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new ALNY positions and 22 closed out — a net gain of 26 holders — while 55 added to existing stakes and 52 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $103M. The largest seller was Citadel Advisors, cutting an estimated $45.6M.
- 164 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2013, up from 139 in Q2 2013.
- Funds reported $3.27B of Alnylam Pharmaceuticals stock for Q3 2013, up 118% quarter-over-quarter.
- 48 funds opened new Alnylam Pharmaceuticals positions in Q3 2013 and 22 closed out, a net change of +26 holders.
- The largest Alnylam Pharmaceuticals buyer in Q3 2013 was Wellington Management Group, an estimated $103M added.
- The largest Alnylam Pharmaceuticals seller in Q3 2013 was Citadel Advisors, an estimated $45.6M sold.
Based on aggregated 13F filings for Q3 2013.